Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update
出版年份 2023 全文链接
标题
Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update
作者
关键词
-
出版物
TUMOR BIOLOGY
Volume -, Issue -, Pages 1-51
出版商
IOS Press
发表日期
2023-11-01
DOI
10.3233/tub-230009
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Updated Prognostic Factors in Localized NSCLC
- (2022) Simon Garinet et al. Cancers
- Association between changes in thioredoxin reductase and other peripheral blood biomarkers with response to PD-1 inhibitor-based combination immunotherapy in non-small cell lung cancer: a retrospective study
- (2022) Shaodi Wen et al. Translational Lung Cancer Research
- The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non‐small cell lung cancer
- (2022) Martin Metzenmacher et al. Thoracic Cancer
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations
- (2021) Juanjuan Dong et al. Cancer Management and Research
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
- (2021) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients
- (2021) Nikolaus Handke et al. Diagnostics
- Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer
- (2021) Oscar Arrieta et al. Clinical Lung Cancer
- Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer
- (2021) Yuzhong Chen et al. Frontiers in Immunology
- Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer
- (2021) Peng Yan et al. BIOSCIENCE REPORTS
- Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer
- (2021) Mirte Muller et al. TUMOR BIOLOGY
- The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types
- (2021) Haiqing Chen et al. Frontiers in Oncology
- Imaging biomarkers for evaluating tumor response: RECIST and beyond
- (2021) Ching-Chung Ko et al. Biomarker Research
- Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer
- (2021) Yin Tang et al. Cancer Management and Research
- Prognostic significance of postoperative longitudinal change of serum carcinoembryonic antigen level in patients with stage I lung adenocarcinoma completely resected by single-port video-assisted thoracic surgery: a retrospective study
- (2021) Hao Chen et al. Translational Lung Cancer Research
- Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
- (2021) Maja Šutić et al. Journal of Personalized Medicine
- Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression
- (2020) Yen-Shou Kuo et al. Scientific Reports
- Significant prognostic determinants in lung cancers of the superior sulcus: comparable analysis of resected and unresected cases
- (2020) Yoshihisa Shimada et al. General Thoracic and Cardiovascular Surgery
- Prognostic Impact of a Novel Tumor Marker and Inflammation Index for Patients With Non-small-cell Lung Cancer
- (2020) MASAKI TOMITA et al. ANTICANCER RESEARCH
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined neat model for the prognosis of postoperative stage III‐N2 non‐small cell lung cancer
- (2020) Yirui Zhai et al. Thoracic Cancer
- Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
- (2020) Zhibo Zhang et al. Frontiers in Immunology
- Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China
- (2020) Muhammad Abbas et al. Frontiers in Oncology
- Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature
- (2020) Laiyan Zhou et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Prognostic nomogram on clinicopathologic features and serum indicators for advanced non-small cell lung cancer patients treated with anti-PD-1 inhibitors
- (2020) Rong Chai et al. Annals of Translational Medicine
- Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma
- (2020) Hung-Jen Chen et al. PLoS One
- Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma
- (2019) L. X. Feng et al. Clinical & Translational Oncology
- Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements
- (2019) Shouying Li et al. MEDICAL SCIENCE MONITOR
- The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
- (2019) M. G. Dal Bello et al. Journal of Translational Medicine
- Redefining treatment paradigms in first-line advanced non-small cell lung cancer
- (2019) David F Heigener et al. CLINICAL CANCER RESEARCH
- Establishment and validation of a novel survival prediction scoring algorithm for patients with non-small-cell lung cancer spinal metastasis
- (2019) Shizhao Zang et al. International Journal of Clinical Oncology
- Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
- (2019) P Hofman et al. ANNALS OF ONCOLOGY
- Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer
- (2019) Akihiro Yoshimura et al. Translational Lung Cancer Research
- The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study
- (2019) P.N. Ding et al. LUNG CANCER
- Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study
- (2019) David Lang et al. LUNG CANCER
- Radiomics with artificial intelligence: a practical guide for beginners
- (2019) Burak Kocak et al. Diagnostic and Interventional Radiology
- Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
- (2019) J. Nicholas Bodor et al. CANCER
- The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
- (2019) Zhen Wu et al. Cancer Management and Research
- Electrochemical biosensors for the detection of lung cancer biomarkers: A review
- (2019) Akbar Khanmohammadi et al. TALANTA
- Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges
- (2019) Erika Rijavec et al. Cancers
- Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non–small Cell Lung Cancer
- (2018) ANTICANCER RESEARCH
- Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer
- (2018) Ae Rin Baek et al. Cancer Biomarkers
- Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
- (2018) Sarah B. Goldberg et al. CLINICAL CANCER RESEARCH
- Biomarker definitions and their applications
- (2018) Robert M Califf EXPERIMENTAL BIOLOGY AND MEDICINE
- The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)
- (2018) Thomas Muley et al. LUNG CANCER
- Radiomics for Response and Outcome Assessment for Non-Small Cell Lung Cancer
- (2018) Liting Shi et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma
- (2018) Hiromichi Shirasu et al. TUMOR BIOLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma
- (2017) Ying He et al. Oncotarget
- Prognostic and predictive value of serum carcinoembryonic antigen levels in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutations and receiving tyrosine kinase inhibitors
- (2017) Xin Min Zhao et al. Oncotarget
- Defining the biological basis of radiomic phenotypes in lung cancer
- (2017) Patrick Grossmann et al. eLife
- PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level
- (2017) Lianjing Cao et al. Journal of Cancer
- Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer
- (2017) Ryo Maeda et al. Journal of Thoracic Disease
- Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer
- (2017) Stefan Holdenrieder et al. Cancer Biomarkers
- Diagnostic relevance of circulating biomarkers in patients with lung cancer
- (2017) Rafael Molina et al. Cancer Biomarkers
- The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited
- (2017) Shaohua Ma et al. Cancer Biomarkers
- Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer
- (2017) Emil Lou et al. Cancer Biomarkers
- The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma
- (2016) Yuki Sato et al. BMC CANCER
- Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
- (2016) Koung Jin Suh et al. Clinical Lung Cancer
- Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations
- (2016) Han Baohui et al. Journal of Cancer Research and Therapeutics
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- (2016) Peter Goldstraw et al. Journal of Thoracic Oncology
- Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer – A survival model with external validation
- (2016) Sara Carvalho et al. RADIOTHERAPY AND ONCOLOGY
- Relationship between serum carcinoembryonic antigen level and epidermal growth factor receptor mutations with the influence on the prognosis of non-small-cell lung cancer patients
- (2016) Zuxun (Peter) Cai OncoTargets and Therapy
- Predictive and prognostic value of preoperative serum tumor markers in resectable adenosqamous lung carcinoma
- (2016) Qiongjie Zhi et al. Oncotarget
- Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis
- (2016) Zipu Yu et al. Oncotarget
- Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer
- (2016) Richeng Jiang et al. Oncotarget
- Postoperative Serum CEA Level is a More Significant Prognostic Factor than Post/Preoperative Serum CEA Ratio in Non-small Cell Cancer Patients
- (2015) Masaki Tomita et al. Asian Pacific Journal of Cancer Prevention
- The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer
- (2015) Ai-Gui Jiang et al. BMC CANCER
- Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer
- (2015) D Korbakis et al. BRITISH JOURNAL OF CANCER
- High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer
- (2015) Y Cui et al. INDIAN JOURNAL OF CANCER
- Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
- (2015) Chee-Seng Tan et al. LANCET ONCOLOGY
- Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib
- (2015) Evelyn M. McKeegan et al. LUNG CANCER
- Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2015) Yu-Mu Chen et al. MEDICINE
- Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer
- (2015) Arthur Cho et al. TUMOR BIOLOGY
- CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients
- (2015) Francesco Facchinetti et al. TUMOR BIOLOGY
- Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer
- (2015) Youtao Xu et al. Scientific Reports
- Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer
- (2015) Zhi-Hui Zhang et al. Cancer Medicine
- High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer
- (2015) Y Cui et al. INDIAN JOURNAL OF CANCER
- Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients
- (2015) Elena Yaiza Romero-Ventosa et al. SpringerPlus
- Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer
- (2014) Xue-Feng Ni et al. Asia-Pacific Journal of Clinical Oncology
- The role of serum carcinoembryonic antigen in predicting responses to chemotherapy and survival in patients with non-small cell lung cancer
- (2014) Yong Song et al. Journal of Cancer Research and Therapeutics
- Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer
- (2014) Shuenn-Wen Kuo et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Serum CA125 level predicts prognosis in patients with multiple brain metastases from non-small cell lung cancer before and after treatment of whole-brain radiotherapy
- (2014) Yue-Can Zeng et al. MEDICAL ONCOLOGY
- Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis
- (2014) Xiao-Bin Wang et al. TUMOR BIOLOGY
- Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma
- (2014) Yanwei Zhang et al. TUMOR BIOLOGY
- Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
- (2013) Akira Ono et al. BMC CANCER
- Usefulness of Serum Carcinoembryonic Antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study
- (2013) Oscar Arrieta et al. BMC CANCER
- The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
- (2013) L. C. Villaruz et al. CLINICAL CANCER RESEARCH
- Overall survival should be the primary endpoint in clinical trials for advanced non-small cell lung cancer
- (2013) P.K. Cheema et al. Current Oncology
- Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer
- (2013) N. Ozeki et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients
- (2013) Dangfan Yu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Prognostic significance of postoperative serum carcinoembryonic antigen levels in patients with completely resected pathological-stage I non-small cell lung cancer
- (2013) Yoshiki Kozu et al. Journal of Cardiothoracic Surgery
- Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR Mutation
- (2013) Kosuke Tanaka et al. Journal of Thoracic Oncology
- Serum neuron-specific enolase levels were associated with the prognosis of small cell lung cancer: a meta-analysis
- (2013) Wei-Xin Zhao et al. TUMOR BIOLOGY
- CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304
- (2012) Martin J. Edelman et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung
- (2012) Seong Yong Park et al. LUNG CANCER
- The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer
- (2012) Anneli Dowler Nygaard et al. LUNG CANCER
- Declines in serum CYFRA21-1 and carcinoembryonic antigen as predictors of chemotherapy response and survival in patients with advanced non-small cell lung cancer
- (2012) LIANG YANG et al. Experimental and Therapeutic Medicine
- Biomarkers, Prediction, and Prognosis in Non–Small-Cell Lung Cancer: A Platform for Personalized Treatment
- (2011) Akshay Sudhindra et al. Clinical Lung Cancer
- Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non–Small-Cell Lung Cancer (NSCLC)
- (2011) Susana Cedrés et al. Clinical Lung Cancer
- American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer
- (2011) Jeffrey M. Peppercorn et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer
- (2011) Takeshi Hanagiri et al. LUNG CANCER
- Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
- (2011) M. Grunnet et al. LUNG CANCER
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib
- (2011) MINKYU JUNG et al. Experimental and Therapeutic Medicine
- The Value of Tumor Markers in Evaluating Chemotherapy Response and Prognosis in Chinese Patients with Advanced Non-Small Cell Lung Cancer
- (2010) Bo Jin et al. CHEMOTHERAPY
- Persistently High Serum Carcinoembryonic Antigen Levels after Surgery Indicate Poor Prognosis in Patients with Stage I Non-Small-Cell Lung Cancer
- (2010) Chien-Ying Wang et al. JOURNAL OF SURGICAL RESEARCH
- Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
- (2010) Lucio Crinò et al. LANCET ONCOLOGY
- Carcinoembryonic Antigen Level in Serum and Pleural Lavage Fluid in Non-Small Cell Lung Cancer
- (2010) M. Tomita et al. THORACIC AND CARDIOVASCULAR SURGEON
- Molecular predictive and prognostic markers in non-small-cell lung cancer
- (2009) Linda E Coate et al. LANCET ONCOLOGY
- EGFR testing in lung cancer is ready for prime time
- (2009) Fred R Hirsch et al. LANCET ONCOLOGY
- Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib
- (2009) Fengsheng Chen et al. MEDICAL ONCOLOGY
- Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients
- (2008) W. Jacot et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
- (2008) Nobuhisa Ishikawa et al. INTERNATIONAL JOURNAL OF CANCER
- Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2008) Panos M. Fidias et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer
- (2008) Mohammad Chakra et al. Journal of Thoracic Oncology
- Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials
- (2007) Anand Rajeswaran et al. LUNG CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started